NCT04569838

A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection in Subjects With Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 91 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a study to evaluate the efficacy and safety of Bendamustine Hydrochloride Injection in subjects with Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas.

Conditions

• Indolent B-Cell Non-Hodgkin's Lymphomas

Interventions

Type	Name	Description
DRUG	Bendamustine hydrochloride injection	Bendamustine is a bifunctional alkylating agent. It cross-links DNA single strand and double strand by alkylation,then destroys the function and synthesis of DNA, and makes the DNA and protein, protein and protein cross-linking, has potential to treat various tumors

Timeline

• Start date: 2012-05-01
• Primary completion: 2016-08-01
• Completion: 2016-08-01
• First posted: 2020-09-30
• Last updated: 2020-09-30

Locations

11 sites across 1 country: China